Abstract
Abstract
The full text of this preprint has been withdrawn by the authors due to author disagreement with the posting of the preprint. Therefore, the authors do not wish this work to be cited as a reference. Questions should be directed to the corresponding author.
Publisher
Research Square Platform LLC
Reference45 articles.
1. The State Council Information Office of the People's Republic of China. Fighting COVID-19: China in Action. 2020. http://www.scio.gov.cn/zfbps/32832/Document/1681809/1681809.htm. Accessed 28 Oct 2022.
2. WHO. WHO Coronavirus (COVID-19) Dashboard. 2022. https://covid19.who.int. Accessed 20 Dec 2022.
3. National Health Commission of the People’s Republic of China. Update on COVID-19 as of 24:00 On 19 Deceember. 2022. http://www.nhc.gov.cn/xcs/yqtb/202212/e25553a06eed4f9dbec6257af9657200.shtml. Accessed 20 Dec 2022.
4. Blocking key mutated hotspot residues in the RBD of the omicron variant (B.1.1.529) with medicinal compounds to disrupt the RBD-hACE2 complex using molecular screening and simulation approaches;Khan A;RSC Adv,2022
5. Comparative genomics, evolutionary epidemiology, and RBD-hACE2 receptor binding pattern in B.1.1.7 (alpha) and B.1.617.2 (delta) related to their pandemic response in UK and India;Chakraborty C;Infect Genet Evol,2022